Line graph showing proportion of clear or almost clear prurigo nodularis investigator global assessment scores throughout the double-blind and open-label extension periods. Vixarelimab at varying doses vs placebo.
Monthly vixarelimab led to rapid and sustained improvement in pruritus and lesion severity for adults with #PrurigoNodularis, with no serious drug-related adverse events reported. ja.ma/4azhD38